Reuters logo
BRIEF-CTI Biopharma announces proposed public offering of convertible preferred stock
June 5, 2017 / 8:22 PM / 4 months ago

BRIEF-CTI Biopharma announces proposed public offering of convertible preferred stock

June 5 (Reuters) - Cti Biopharma Corp

* CTI Biopharma announces proposed public offering of convertible preferred stock

* ‍Each share of series N-3 preferred stock will have a stated value of $1,000 per share​

* CTI plans to use net proceeds from this offering in part to conduct pac203 clinical trial, submit new MAA for pacritinib to EMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below